TriangleNCT01772719 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- At start of year 2 of follow-up on all surviving participants
What was measured
OS(Overall survival) is measured from date of study enrollment until death.
Analysis population: Study was terminated and PI has left the institution. Sincere efforts were made to gather and report the data, however, no data is available for the study
Groups in this outcome
Simvastatin and Zoledronic Acid
Simvastatin and zoledronic acid: 1. Simvastatin 80 mg PO daily starting two days before starting chemotherapy and stopping two days after chemotherapy. 2. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly.
| Group | Source count |
|---|---|
| Simvastatin and Zoledronic Acid | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- description
- OS(Overall survival) is measured from date of study enrollment until death.
- groups
- description
- Simvastatin and zoledronic acid: 1. Simvastatin 80 mg PO daily starting two days before starting chemotherapy and stopping two days after chemotherapy. 2. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly.
- id
- OG000
- title
- Simvastatin and Zoledronic Acid
- population Description
- Study was terminated and PI has left the institution. Sincere efforts were made to gather and report the data, however, no data is available for the study
- reporting Status
- POSTED
- time Frame
- At start of year 2 of follow-up on all surviving participants
- title
- Overall Survival
- type
- SECONDARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice